logo
Where AI Meets Empathy: How Huntica's Actor-Led Interviews Are Re‑wiring Talent Acquisition

Where AI Meets Empathy: How Huntica's Actor-Led Interviews Are Re‑wiring Talent Acquisition

Wilmington, DE June 03, 2025 --( PR.com )-- With unemployment in the United States hovering near historic lows, the talent war is only getting fiercer. According to the Society for Human Resource Management's 2024 Talent Acquisition Benchmarking Report, recruiters now spend an average of 44 days filling a role, up from 31 days just two years ago (Source 1). Meanwhile, a CareerBuilder Candidate‑Experience Survey 2023 found that 60 % of applicants abandon the process when it drags or feels impersonal (Source 2). Yet 66 % say a positive experience is the deciding factor in whether they accept an offer (IBM Smarter Workforce Institute, 2024 – Source 3).
Enter Huntica, the virtual‑interview platform from Boson Group Inc. spearheaded by Co‑Founder and Chief Product Officer Dmitry Gopalov. Huntica merges natural‑language AI with prerecorded performances by professional actors, allowing candidates to converse with an avatar that waits, nods and even cracks a gentle joke—capturing the warmth of a live meeting while giving hiring teams structured, bias‑checked data.
'Technology should compress the timeline, not compress the human,' Gopalov says. 'We built Huntica so every applicant feels heard, and every recruiter sees clean analytics they can trust—no more guessing from gut feel.'
Huntica's Impact at a Glance:
Time Spent by Recruiters on First-Round Screens:
Previously, recruiters spent around 10 hours per vacancy. With Huntica, that time has been cut by 70%, saving 7 hours per position.
Average Time-to-Hire:
What used to take 44 days now takes just 16 days — a 64% acceleration in hiring speed.
Candidate Drop-Off Mid-Process:
Huntica has helped reduce mid-process candidate drop-off from 26% down to 7%, ensuring stronger candidate engagement and process completion. Source 4: Boson Group internal usage study, Q1 2025.
Nearly 68 % of U.S. employers expect to use AI in hiring by the end of 2025, according to Deloitte's 2025 Global Human Capital Trends Survey (Source 5). That appetite feeds a global recruitment‑software market already worth about US $3 billion and projected to grow 9 % annually through 2030, says Grand View Research (Recruitment Software Market Report 2024 – Source 6).
'The winners will be the platforms that prove you can automate the dull work and preserve empathy,' Gopalov adds. 'That balance is table stakes for Gen‑AI compliance, brand reputation and—frankly—basic decency.'
Huntica is already live worldwide but continues to prioritise U.S. clients, working with enterprise and mid‑market organisations across technology, retail and logistics. The company plans further expansion in Europe and Asia‑Pacific later this year.
Huntica, a Boson Group solution, blends conversational AI with professional actors' performances to deliver authentic, bias‑aware virtual interviews at scale. Founded in 2024 and headquartered in Sofia, Bulgaria, Huntica helps organisations cut time‑to‑hire, boost candidate satisfaction and improve diversity outcomes.
Sources
Society for Human Resource Management (SHRM), '2024 Talent Acquisition Benchmarking Report.'
CareerBuilder, 'Candidate Experience Survey 2023.'
IBM Smarter Workforce Institute, 'Global Recruiting Trends 2024.'
Boson Group internal usage study, Q1 2025.
Deloitte, '2025 Global Human Capital Trends Survey.'
Grand View Research, 'Recruitment Software Market Size Report 2024.'
Contact Information:
Huntica
Dmitry Gopalov
+359883388311
Contact via Email
huntica.works
Read the full story here: Where AI Meets Empathy: How Huntica's Actor-Led Interviews Are Re‑wiring Talent Acquisition
Press Release Distributed by PR.com

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Chocolate company recalls product nationwide for undeclared allergen
Chocolate company recalls product nationwide for undeclared allergen

Yahoo

time8 minutes ago

  • Yahoo

Chocolate company recalls product nationwide for undeclared allergen

NEW YORK (PIX11) — Chocolate products have been recalled nationwide due to potential undeclared milk allergens, according to the U.S. Food and Drug Administration. The Pennsylvania-based distributor, Weaver Nut Company, Inc., has recalled its semi-sweet chocolate nonpareils with white or Christmas colored seeds, the advisory from the FDA says. More Local News People who have an allergy or severe sensitivity to milk could face serious or life-threatening allergic reactions if they consume the impacted products, the FDA warns. So far no illnesses have been reported. The issue was discovered through a wholesale customer who filed a complaint saying the shipment was misaligned with the product specifications. Lab tests confirmed the presence of milk in the product. More: Latest News from Around the Tri-State Consumers who have purchased the recalled product are urged not to eat it if they have a milk allergy and return it to the place of purchase for a full refund. Below is the list of lot codes for the affected chocolates. 47518 – Nonpareil, Semi-Sweet Chocolate (Christmas Seeds) 204206 204207 204208 204209 204212 224225 D2645 – Nonpareils, Semi-Sweet Chocolate (White Seeds) 204214-RL 204214 204215 224221 224222 224223 135215 135216 135217 135220 135221 145204 145205-1 145207-1 145210-1 Dominique Jack is a digital content producer from Brooklyn with more than five years of experience covering news. She joined PIX11 in 2024. More of her work can be found here. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors
Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors

Yahoo

time8 minutes ago

  • Yahoo

Workiva Inc. (WK) Appoints Astha Malik to Its Board of Directors

Workiva Inc. (NYSE:WK) is one of the 11 Best Tech Stocks to Buy On the Dip. On May 29, Workiva Inc. (NYSE:WK) announced the appointment of Astha Malik, Chief Business Officer of Braze, to its board of directors. Malik brings 25 years of experience in driving growth and scaling high-growth SaaS companies. The company also released its Q1 2025 results on May 1. The revenue of $206 million grew 17% year-over-year driven by a 20% increase in subscription and support revenue. Both of these financial indicators surpass management's guidance despite a challenging environment characterized by a cautious buying environment and flat professional services revenue. A software engineer debugging a compliance code on a laptop in a modern office setting. After the earnings release, analyst Alexander Sklar from Raymond James maintained an Overweight rating on Workiva Inc. (NYSE:WK) lowering the price target from $125 to $105. The analyst noted the company showed strong bookings in Q1 however, the tough macroeconomic environment led to a conservative outlook by Raymond James. Regardless, Workiva Inc. (NYSE:WK) maintained its full-year revenue guidance at $864 million to $868 million. Workiva Inc. (NYSE:WK) is a technology company that operates a cloud-based platform that enables organizations to streamline and automate financial, sustainability, and compliance reporting processes. Its SaaS platform combines ERP, HCM, and CRM applications, supporting real-time collaboration and integrated reporting across teams. While we acknowledge the potential of WK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Melden Sie sich an, um Ihr Portfolio aufzurufen.

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

Yahoo

time9 minutes ago

  • Yahoo

Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a 'Buy' rating and a $72 price target. The research firm remains bullish about the company's prospects owing to the strong potential of its drug candidates. A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The company's partnership with Takeda on Rusfertide to treat polycythemia Vera (PV) and oral IL-23 (icotrokinra) is one of the developments that underscore the research firm's favorable rating. Rusfertide demonstrated strong potential in PV patients in phase 3 trials, affirming its potential to address unmet needs. Citi is especially bullish about adding Rusfertide to existing therapies to expand its use case. In addition, the firm echoed the company's strategic partnership with Johnson & Johnson for multiple inflammation indications. According to Citi, Protagonist Therapeutics shares have outperformed over the past three months, going up by a 40% gain compared to a 2% gain of the S&P 500. It expects the company's combined revenues to climb to $700 million by 2032, above consensus estimates of $680 million. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a biopharmaceutical company that develops peptide-based drugs to treat various diseases, including rare and prevalent ones. Its pipeline includes treatments for blood disorders like polycythemia Vera and inflammatory conditions like ulcerative colitis and psoriasis. While we acknowledge the potential of PTGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store